Understand the Clover Health Ruling, Rethink Coding and Documentation in a Value-Based Care Environment
The ruling points to the need for proactive documentation. The Medicare Advantage (MA) Star Ratings program has long served as both a quality benchmark and a financial engine for health plans. That foundation was shaken in May 2026, when a federal court ruled in favor of Clover Health, finding that the Centers for Medicare & Medicaid Services (CMS) improperly calculated its 2026 Star Rating. The decision, and CMS’ subsequent response, has introduced new uncertainty into how organizations approach quality, risk, and revenue strategy and plays a central role in how value-based care outcomes are measured, validated, and financially rewarded. Understand the Ruling’s Industry-wide Implications Clover Health’s lawsuit centered on a drop in its largest preferred provider organization (PPO) contract from 4.0 to 3.5 stars, falling below the threshold for full quality bonus payments and materially reducing its bonus revenue opportunity. The company argued that CMS used measures it was not authorized to include and failed to follow required rulemaking procedures. The court agreed on both counts, determining that: As a result, the court ordered CMS to recalculate Clover’s rating. CMS then took the unusual step of recalculating ratings more broadly, though only applying changes if they improved a plan’s score and allowing affected plans to revise their bids. Find Out the Ruling’s Stakes and Strategic Volatility Star ratings are not just a report card — they are directly tied to revenue. Plans that achieve four stars or higher qualify for higher quality bonus payments, which can translate to billions of dollars across the industry. For Clover alone, the initial downgrade represented an estimated $120 million in lost payments. More broadly, the ruling introduces three key dynamics: In short, plans can no longer treat star ratings as a fixed target. Instead, they must navigate a moving framework where measurement, compliance, and financial outcomes are increasingly interconnected and contested. Know What the Clover Ruling Signals for Coding, Documentation, and Compliance While much of the attention has focused on the legal and financial implications, the Clover ruling also highlights a deeper operational reality: Star rating integrity depends on underlying data integrity, and that data begins with coding and documentation. Three implications stand out: 1. Documentation is no longer passive — it is regulatory evidence. The court’s focus on allowable data sources reinforces that every measure used in star ratings must be traceable back to compliant, auditable inputs. Clinical documentation must support not only care delivery, but also regulatory defensibility. Inaccurate, incomplete, or inconsistently captured data introduces both performance risk and compliance exposure. 2. Coding accuracy directly affects quality measurement. Many star measures rely on coded data to identify numerator/denominator populations, adherence, and outcomes. Variability in coding and coding-adjacent practices, whether in diagnosis capture, medication adherence indicators, or encounter data submission, can materially impact measured performance. As scrutiny increases, the tolerance for coding inconsistency decreases. 3. Retrospective correction is insufficient in a real-time environment. Traditional “look-back” approaches — such as retrospective chart review, gap chasing, and late-cycle documentation fixes — are largely reactionary and increasingly mismatched to a system that expects continuous, validated data flow. By the time issues are identified retrospectively, they may already be embedded in reported performance or regulatory submissions. View the Emerging Mandate: Audit-Ready, Prospective Data Integrity Together, these dynamics point to a clear shift: Plans must treat coding, documentation, and data capture as proactive compliance functions, not downstream administrative tasks. This requires a more integrated approach across clinical, coding, and compliance teams: Just as importantly, organizations must ensure that data flowing into quality measurement programs is consistent, standardized, and supported by clear governance, particularly as regulatory scrutiny increases. Beware The Bottom Line The Clover ruling is a clear signal: The star ratings and quality measurement landscape is evolving, and organizations must be prepared for both regulatory disruption and heightened scrutiny. While methodologies may change, one principle is becoming more firmly established: Quality scores are only as reliable as the data that underpin them. In this environment, excellence in coding, documentation, and compliance is no longer ancillary to star performance, it is foundational. This shift is even more consequential in the context of value-based care. As reimbursement models increasingly tie financial outcomes to quality, risk accuracy, and demonstrable patient outcomes, the same documentation and coding practices that support star ratings also drive success across value-based arrangements. Inaccurate or incomplete data does not just affect a plan’s rating; it can distort risk adjustment, misrepresent quality performance, and ultimately undermine the financial and clinical integrity of value-based contracts. As a result, organizations that invest in accurate, timely, and audit-ready data practices position themselves to succeed on multiple fronts: They improve star performance, strengthen compliance posture, and enable more precise alignment between clinical care and financial outcomes. In a system where payment is increasingly determined by what can be proven — not just what is done — coding and documentation become the connective tissue between care delivery, quality measurement, and value realization. Organizations that recognize and operationalize this reality will be best positioned not only to navigate regulatory volatility, but to lead in a healthcare environment where value, transparency, and accountability are inseparable. Dawn Carter, MHA, CPC, CRC, CPMA, CDEO, CPCO, AAPC Fellow, National Advisory Board
The decision creates a legal pathway for other plans to challenge ratings, raising the possibility of ongoing disputes and recalculations.
Analysts warn the ruling may signal a more volatile direction for star ratings, particularly as CMS balances regulatory reform with legal constraints.
The court emphasized statutory data sources (e.g., HEDIS, HOS, CAHPS), reinforcing that performance measurement must be grounded in clearly authorized, validated, and auditable data.
(A version of this article first appeared on the AAPC Knowledge Center blog)
